Global Neuroendocrine Carcinoma Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023

  • receipt Report ID : 147420
  • calendar_today Published On: Apr, 2019
  • file_copy Pages: 133
  • list Pharmaceuticals and Healthcare

Neuroendocrine tumors (NETs) are neoplasms that arise from cells of the endocrine (hormonal) and nervous systems. Many are benign, while some are malignant. They most commonly occur in the intestine, where they are often called carcinoid tumors, but they are also found in the pancreas, lung and the rest of the body.

Scope of the Report:

This report focuses on the Neuroendocrine Carcinoma in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

The somatostatin analogs segment by treatment type is expected to witness high traction in the coming years.

The worldwide market for Neuroendocrine Carcinoma is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study.

Market Segment by Manufacturers, this report covers

Pfizer

Novartis

Chiasma

Ipsen

Abbvie

Valeant

Jubilant

Teva

F.Hoffmann-La Roche

Advanced Accelerator

Mateon

Lexicon

Market Segment by Regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia etc.)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers

Chemotherapy

Somatostatin Analogs

Targeted Therapy

Market Segment by Applications, can be divided into

Hospital

Clinics

Oncology Centres

Ambulatory Surgery Centres

There are 15 Chapters to deeply display the global Neuroendocrine Carcinoma market.

Chapter 1, to describe Neuroendocrine Carcinoma Introduction, product scope, market overview, market opportunities, market risk, market driving force;

Chapter 2, to analyze the top manufacturers of Neuroendocrine Carcinoma, with sales, revenue, and price of Neuroendocrine Carcinoma, in 2016 and 2017;

Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;

Chapter 4, to show the global market by regions, with sales, revenue and market share of Neuroendocrine Carcinoma, for each region, from 2013 to 2018;

Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;

Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;

Chapter 12, Neuroendocrine Carcinoma market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;

Chapter 13, 14 and 15, to describe Neuroendocrine Carcinoma sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source

Frequently Asked Questions

The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.

Market is segmented on the basis:

  • By Type
  • By Application
  • By Region
  • By Country
  • By Manufacturer

The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.

The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.

Table of Contents

1 Market Overview

1.1 Neuroendocrine Carcinoma Introduction

1.2 Market Analysis by Type

1.2.1 Chemotherapy

1.2.2 Somatostatin Analogs

1.2.3 Targeted Therapy

1.3 Market Analysis by Applications

1.3.1 Hospital

1.3.2 Clinics

1.3.3 Oncology Centres

1.3.4 Ambulatory Surgery Centres

1.4 Market Analysis by Regions

1.4.1 North America (United States, Canada and Mexico)

1.4.1.1 United States Market States and Outlook (2013-2023)

1.4.1.2 Canada Market States and Outlook (2013-2023)

1.4.1.3 Mexico Market States and Outlook (2013-2023)

1.4.2 Europe (Germany, France, UK, Russia and Italy)

1.4.2.1 Germany Market States and Outlook (2013-2023)

1.4.2.2 France Market States and Outlook (2013-2023)

1.4.2.3 UK Market States and Outlook (2013-2023)

1.4.2.4 Russia Market States and Outlook (2013-2023)

1.4.2.5 Italy Market States and Outlook (2013-2023)

1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

1.4.3.1 China Market States and Outlook (2013-2023)

1.4.3.2 Japan Market States and Outlook (2013-2023)

1.4.3.3 Korea Market States and Outlook (2013-2023)

1.4.3.4 India Market States and Outlook (2013-2023)

1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)

1.4.4 South America, Middle East and Africa

1.4.4.1 Brazil Market States and Outlook (2013-2023)

1.4.4.2 Egypt Market States and Outlook (2013-2023)

1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)

1.4.4.4 South Africa Market States and Outlook (2013-2023)

1.4.4.5 Nigeria Market States and Outlook (2013-2023)

1.5 Market Dynamics

1.5.1 Market Opportunities

1.5.2 Market Risk

1.5.3 Market Driving Force

2 Manufacturers Profiles

2.1 Pfizer

2.1.1 Business Overview

2.1.2 Neuroendocrine Carcinoma Type and Applications

2.1.2.1 Product A

2.1.2.2 Product B

2.1.3 Pfizer Neuroendocrine Carcinoma Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.2 Novartis

2.2.1 Business Overview

2.2.2 Neuroendocrine Carcinoma Type and Applications

2.2.2.1 Product A

2.2.2.2 Product B

2.2.3 Novartis Neuroendocrine Carcinoma Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.3 Chiasma

2.3.1 Business Overview

2.3.2 Neuroendocrine Carcinoma Type and Applications

2.3.2.1 Product A

2.3.2.2 Product B

2.3.3 Chiasma Neuroendocrine Carcinoma Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.4 Ipsen

2.4.1 Business Overview

2.4.2 Neuroendocrine Carcinoma Type and Applications

2.4.2.1 Product A

2.4.2.2 Product B

2.4.3 Ipsen Neuroendocrine Carcinoma Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.5 Abbvie

2.5.1 Business Overview

2.5.2 Neuroendocrine Carcinoma Type and Applications

2.5.2.1 Product A

2.5.2.2 Product B

2.5.3 Abbvie Neuroendocrine Carcinoma Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.6 Valeant

2.6.1 Business Overview

2.6.2 Neuroendocrine Carcinoma Type and Applications

2.6.2.1 Product A

2.6.2.2 Product B

2.6.3 Valeant Neuroendocrine Carcinoma Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.7 Jubilant

2.7.1 Business Overview

2.7.2 Neuroendocrine Carcinoma Type and Applications

2.7.2.1 Product A

2.7.2.2 Product B

2.7.3 Jubilant Neuroendocrine Carcinoma Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.8 Teva

2.8.1 Business Overview

2.8.2 Neuroendocrine Carcinoma Type and Applications

2.8.2.1 Product A

2.8.2.2 Product B

2.8.3 Teva Neuroendocrine Carcinoma Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.9 F.Hoffmann-La Roche

2.9.1 Business Overview

2.9.2 Neuroendocrine Carcinoma Type and Applications

2.9.2.1 Product A

2.9.2.2 Product B

2.9.3 F.Hoffmann-La Roche Neuroendocrine Carcinoma Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.10 Advanced Accelerator

2.10.1 Business Overview

2.10.2 Neuroendocrine Carcinoma Type and Applications

2.10.2.1 Product A

2.10.2.2 Product B

2.10.3 Advanced Accelerator Neuroendocrine Carcinoma Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.11 Mateon

2.11.1 Business Overview

2.11.2 Neuroendocrine Carcinoma Type and Applications

2.11.2.1 Product A

2.11.2.2 Product B

2.11.3 Mateon Neuroendocrine Carcinoma Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.12 Lexicon

2.12.1 Business Overview

2.12.2 Neuroendocrine Carcinoma Type and Applications

2.12.2.1 Product A

2.12.2.2 Product B

2.12.3 Lexicon Neuroendocrine Carcinoma Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

3 Global Neuroendocrine Carcinoma Sales, Revenue, Market Share and Competition by Manufacturer (2016-2017)

3.1 Global Neuroendocrine Carcinoma Sales and Market Share by Manufacturer (2016-2017)

3.2 Global Neuroendocrine Carcinoma Revenue and Market Share by Manufacturer (2016-2017)

3.3 Market Concentration Rate

3.3.1 Top 3 Neuroendocrine Carcinoma Manufacturer Market Share in 2017

3.3.2 Top 6 Neuroendocrine Carcinoma Manufacturer Market Share in 2017

3.4 Market Competition Trend

4 Global Neuroendocrine Carcinoma Market Analysis by Regions

4.1 Global Neuroendocrine Carcinoma Sales, Revenue and Market Share by Regions

4.1.1 Global Neuroendocrine Carcinoma Sales and Market Share by Regions (2013-2018)

4.1.2 Global Neuroendocrine Carcinoma Revenue and Market Share by Regions (2013-2018)

4.2 North America Neuroendocrine Carcinoma Sales and Growth Rate (2013-2018)

4.3 Europe Neuroendocrine Carcinoma Sales and Growth Rate (2013-2018)

4.4 Asia-Pacific Neuroendocrine Carcinoma Sales and Growth Rate (2013-2018)

4.5 South America Neuroendocrine Carcinoma Sales and Growth Rate (2013-2018)

4.6 Middle East and Africa Neuroendocrine Carcinoma Sales and Growth Rate (2013-2018)

5 North America Neuroendocrine Carcinoma by Countries

5.1 North America Neuroendocrine Carcinoma Sales, Revenue and Market Share by Countries

5.1.1 North America Neuroendocrine Carcinoma Sales and Market Share by Countries (2013-2018)

5.1.2 North America Neuroendocrine Carcinoma Revenue and Market Share by Countries (2013-2018)

5.2 United States Neuroendocrine Carcinoma Sales and Growth Rate (2013-2018)

5.3 Canada Neuroendocrine Carcinoma Sales and Growth Rate (2013-2018)

5.4 Mexico Neuroendocrine Carcinoma Sales and Growth Rate (2013-2018)

6 Europe Neuroendocrine Carcinoma by Countries

6.1 Europe Neuroendocrine Carcinoma Sales, Revenue and Market Share by Countries

6.1.1 Europe Neuroendocrine Carcinoma Sales and Market Share by Countries (2013-2018)

6.1.2 Europe Neuroendocrine Carcinoma Revenue and Market Share by Countries (2013-2018)

6.2 Germany Neuroendocrine Carcinoma Sales and Growth Rate (2013-2018)

6.3 UK Neuroendocrine Carcinoma Sales and Growth Rate (2013-2018)

6.4 France Neuroendocrine Carcinoma Sales and Growth Rate (2013-2018)

6.5 Russia Neuroendocrine Carcinoma Sales and Growth Rate (2013-2018)

6.6 Italy Neuroendocrine Carcinoma Sales and Growth Rate (2013-2018)

7 Asia-Pacific Neuroendocrine Carcinoma by Countries

7.1 Asia-Pacific Neuroendocrine Carcinoma Sales, Revenue and Market Share by Countries

7.1.1 Asia-Pacific Neuroendocrine Carcinoma Sales and Market Share by Countries (2013-2018)

7.1.2 Asia-Pacific Neuroendocrine Carcinoma Revenue and Market Share by Countries (2013-2018)

7.2 China Neuroendocrine Carcinoma Sales and Growth Rate (2013-2018)

7.3 Japan Neuroendocrine Carcinoma Sales and Growth Rate (2013-2018)

7.4 Korea Neuroendocrine Carcinoma Sales and Growth Rate (2013-2018)

7.5 India Neuroendocrine Carcinoma Sales and Growth Rate (2013-2018)

7.6 Southeast Asia Neuroendocrine Carcinoma Sales and Growth Rate (2013-2018)

8 South America Neuroendocrine Carcinoma by Countries

8.1 South America Neuroendocrine Carcinoma Sales, Revenue and Market Share by Countries

8.1.1 South America Neuroendocrine Carcinoma Sales and Market Share by Countries (2013-2018)

8.1.2 South America Neuroendocrine Carcinoma Revenue and Market Share by Countries (2013-2018)

8.2 Brazil Neuroendocrine Carcinoma Sales and Growth Rate (2013-2018)

8.3 Argentina Neuroendocrine Carcinoma Sales and Growth Rate (2013-2018)

8.4 Colombia Neuroendocrine Carcinoma Sales and Growth Rate (2013-2018)

9 Middle East and Africa Neuroendocrine Carcinoma by Countries

9.1 Middle East and Africa Neuroendocrine Carcinoma Sales, Revenue and Market Share by Countries

9.1.1 Middle East and Africa Neuroendocrine Carcinoma Sales and Market Share by Countries (2013-2018)

9.1.2 Middle East and Africa Neuroendocrine Carcinoma Revenue and Market Share by Countries (2013-2018)

9.2 Saudi Arabia Neuroendocrine Carcinoma Sales and Growth Rate (2013-2018)

9.3 UAE Neuroendocrine Carcinoma Sales and Growth Rate (2013-2018)

9.4 Egypt Neuroendocrine Carcinoma Sales and Growth Rate (2013-2018)

9.5 Nigeria Neuroendocrine Carcinoma Sales and Growth Rate (2013-2018)

9.6 South Africa Neuroendocrine Carcinoma Sales and Growth Rate (2013-2018)

10 Global Neuroendocrine Carcinoma Market Segment by Type

10.1 Global Neuroendocrine Carcinoma Sales, Revenue and Market Share by Type (2013-2018)

10.1.1 Global Neuroendocrine Carcinoma Sales and Market Share by Type (2013-2018)

10.1.2 Global Neuroendocrine Carcinoma Revenue and Market Share by Type (2013-2018)

10.2 Chemotherapy Sales Growth and Price

10.2.1 Global Chemotherapy Sales Growth (2013-2018)

10.2.2 Global Chemotherapy Price (2013-2018)

10.3 Somatostatin Analogs Sales Growth and Price

10.3.1 Global Somatostatin Analogs Sales Growth (2013-2018)

10.3.2 Global Somatostatin Analogs Price (2013-2018)

10.4 Targeted Therapy Sales Growth and Price

10.4.1 Global Targeted Therapy Sales Growth (2013-2018)

10.4.2 Global Targeted Therapy Price (2013-2018)

11 Global Neuroendocrine Carcinoma Market Segment by Application

11.1 Global Neuroendocrine Carcinoma Sales Market Share by Application (2013-2018)

11.2 Hospital Sales Growth (2013-2018)

11.3 Clinics Sales Growth (2013-2018)

11.4 Oncology Centres Sales Growth (2013-2018)

11.5 Ambulatory Surgery Centres Sales Growth (2013-2018)

12 Neuroendocrine Carcinoma Market Forecast (2018-2023)

12.1 Global Neuroendocrine Carcinoma Sales, Revenue and Growth Rate (2018-2023)

12.2 Neuroendocrine Carcinoma Market Forecast by Regions (2018-2023)

12.2.1 North America Neuroendocrine Carcinoma Market Forecast (2018-2023)

12.2.2 Europe Neuroendocrine Carcinoma Market Forecast (2018-2023)

12.2.3 Asia-Pacific Neuroendocrine Carcinoma Market Forecast (2018-2023)

12.2.4 South America Neuroendocrine Carcinoma Market Forecast (2018-2023)

12.2.5 Middle East and Africa Neuroendocrine Carcinoma Market Forecast (2018-2023)

12.3 Neuroendocrine Carcinoma Market Forecast by Type (2018-2023)

12.3.1 Global Neuroendocrine Carcinoma Sales Forecast by Type (2018-2023)

12.3.2 Global Neuroendocrine Carcinoma Market Share Forecast by Type (2018-2023)

12.4 Neuroendocrine Carcinoma Market Forecast by Application (2018-2023)

12.4.1 Global Neuroendocrine Carcinoma Sales Forecast by Application (2018-2023)

12.4.2 Global Neuroendocrine Carcinoma Market Share Forecast by Application (2018-2023)

13 Sales Channel, Distributors, Traders and Dealers

13.1 Sales Channel

13.1.1 Direct Marketing

13.1.2 Indirect Marketing

13.1.3 Marketing Channel Future Trend

13.2 Distributors, Traders and Dealers

14 Research Findings and Conclusion

15 Appendix

15.1 Methodology

15.2 Data Source

List of Tables and Figures

Figure Neuroendocrine Carcinoma Picture

Table Product Specifications of Neuroendocrine Carcinoma

Figure Global Sales Market Share of Neuroendocrine Carcinoma by Types in 20

Please fill the form below, to recieve the report sample


+1

Choose License Type

Reach Us

Email us at

sales@mrinsights.biz

Or call us on

US +1-201-465-4211

IND +91-906-779-0957

Why Choose Us

ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems

Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system

Global Outreach6 Major regions and 40+ countries level analysis accomplished

Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery